Proxalin-Plus

Quick links to important sections

Proxalin-Plus

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Proxalin-Plus

Quick Facts

Property Description
Active ingredient Acetaminophen, Naproxen Sodium
Form Oral tablet (Fixed-dose combination)
Pharmacological class Non-opioid Analgesic, NSAID, Antipyretic
Common use Relief of pain, inflammation, and fever
Origin Synthetic compound

What Type of Medicine is Proxalin-Plus?

Proxalin-Plus is defined as a synthetic, fixed-dose combination product simultaneously classified as a non-opioid analgesic, an antipyretic, and a Non-Steroidal Anti-Inflammatory Drug (NSAID). This oral tablet combines two distinct active pharmaceutical ingredients to achieve a synergistic therapeutic effect. Naproxen Sodium belongs to the propionic acid derivatives group, which is a key subclass of NSAIDs.

This specific combination is clinically recognized for efficacy in managing moderate pain conditions. Unlike single-component drugs, Proxalin-Plus targets both the pain signals in the central nervous system and the local chemical mediators responsible for inflammation and fever in the periphery, offering a broader approach to relief.


Composition: Acetaminophen and Naproxen Sodium Combined

The core active ingredients in Proxalin-Plus are Acetaminophen (Paracetamol) and Naproxen Sodium. The composition features Acetaminophen, a widely used agent for treating pain and fever. In contrast, Naproxen Sodium provides a strong anti-inflammatory effect by inhibiting the pro-inflammatory enzyme cyclooxygenase (COX).

The rationale for this combination is rooted in evidence demonstrating that the distinct mechanisms of these two different classes of agents provide enhanced efficacy against pain, inflammation, and fever compared to single-ingredient use. This dual mechanism ensures the medicine addresses both the sensation of pain and the underlying inflammatory process.


General Purpose and Core Benefit

The general purpose of Proxalin-Plus is to provide effective, simultaneous relief from multiple symptoms, particularly pain, inflammation, and fever. The medicine is designed for patients who require the distinct, complementary actions of an NSAID alongside a non-opioid analgesic. This dual action offers a core benefit: the comprehensive physiological approach ensures the medicine optimizes pain control through a synergistic effect, managing symptoms such as discomfort associated with acute conditions.

Regulatory References

  1. NIH StatPearls: Acetaminophen

What side effects are possible with Proxalin-Plus?

Possible Side Effects and Safety Information

Proxalin-Plus is associated with potential risks that are explicitly outlined in regulatory warnings, including a Boxed Warning regarding serious cardiovascular and gastrointestinal events.

Serious and Clinically Significant Risks

  • Cardiovascular Thrombotic Events: Use of this medication may increase the risk of serious, potentially fatal, cardiovascular thrombotic events, such as myocardial infarction (heart attack) and stroke. This risk can begin early in treatment and may increase with prolonged use or higher doses. The drug is contraindicated for pain treatment after coronary artery bypass graft (CABG) surgery.
  • Gastrointestinal Adverse Events: Nonsteroidal anti-inflammatory drugs (NSAIDs) carry a risk of serious gastrointestinal events, including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time without warning. Elderly patients and those with a prior history of GI bleeding are at greater risk.
  • Other Serious Adverse Reactions: Severe, sometimes fatal, skin reactions (like Stevens-Johnson Syndrome) and serious allergic-type reactions (anaphylactoid reactions) have been documented. The drug may also cause or worsen conditions like hypertension, heart failure, and renal or hepatic toxicity.

Common Adverse Reactions

The most commonly reported side effects typically involve the gastrointestinal and nervous systems. These include dyspepsia (heartburn), nausea, abdominal pain, headache, and dizziness.

Population-Specific Safety Considerations

  • Elderly: Patients over the age of 65 are at a higher risk for serious gastrointestinal and renal adverse events.
  • Pregnancy: Use after approximately 20 weeks of pregnancy is discouraged due to potential harm to the fetus and complications at delivery; use is strictly contraindicated from around 30 weeks gestation.
  • Asthma: The drug is contraindicated in patients with aspirin-sensitive asthma due to the risk of severe asthma exacerbation.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information emphasizes that the use of opioid pain medicines, such as Proxalin-Plus, carries a significant risk of fatal and non-fatal overdose. This risk is known to be increased with higher doses and persists throughout the duration of long-term therapy.


Documented Overdose Manifestations

Overdose primarily targets the respiratory and central nervous systems. Clinical manifestations, as described in official documents, include:

  • Life-threatening respiratory problems: This involves slowed, shallow, or difficult breathing.
  • Central Nervous System (CNS) depression: Symptoms such as severe sleepiness or the inability to respond or wake up are key indicators.

Required Emergency Action

Immediate medical help is required if any symptoms of overdose are observed. The official regulatory instruction is to seek emergency medical help or call 911 immediately.

Specific emergency response statements also note the availability and use of opioid reversal agents, such as naloxone or nalmefene, which can temporarily counteract an overdose. The prescribing information for this class of medicine is mandated to address the risks of misuse, abuse, addiction, and overdose.

Therapeutic Uses of Proxalin-Plus

The primary therapeutic role of Proxalin-Plus may be to support the easing of symptoms related to a combination of pain, inflammation, and fever. The fixed-dose combination is applied across domains where additional symptomatic support is needed for challenging episodic symptoms.

The medicine is commonly used to help manage acute and recurrent symptomatic discomfort, including muscular aches, minor pain associated with arthritis, headaches, menstrual cramps (dysmenorrhea), and discomfort following minor procedures such as dental extractions. The active components are used in settings where additional symptomatic support is needed, aligning with therapeutic uses for naproxen.

Proxalin-Plus helps address symptom clusters that may become intense or disruptive, such as the co-occurrence of pain, swelling, and stiffness in inflammatory conditions, or the systemic symptoms of pain and fever during acute illness. The medication provides support that helps ease the overall symptom burden during difficult episodes.


Quick Facts: Symptomatic Support for Pain, Inflammation, and Fever

Category Typical Use Case
Symptom Focus Pain, Inflammation, and Fever (Simultaneous Relief)
Clinical Context Musculoskeletal conditions, Acute episodes (e.g., menstrual cramps, gout), and Post-procedure discomfort.
Patient Benefit Supports general well-being and assists with easing discomfort when symptoms interfere with routine activities.

Eligibility and Restrictions for Use

Who Can and Cannot Use Proxalin-Plus?

Eligibility for Proxalin-Plus, a combination of acetaminophen and naproxen sodium (an NSAID), is determined by regulatory guidelines concerning age, pregnancy status, and pre-existing medical conditions.


Populations for Whom Use is Prohibited or Restricted

Category Regulatory Statement (Must Not Use / Avoid Use)
Absolute Contraindications Patients with known hypersensitivity or allergic-type reaction to Naproxen, Acetaminophen, Aspirin, or other NSAIDs; patients undergoing Coronary Artery Bypass Graft (CABG) surgery; and pregnant patients at 30 weeks gestation and later (late pregnancy).
Avoid Use Conditions Patients with Advanced Renal Disease, Severe Heart Failure, or Severe Renal Impairment (creatinine clearance < 30 mL/min).

Age and Conditional Eligibility

Age Restrictions: The medicine is officially indicated for Adults and Children 12 years and older. Use in children under 12 is not established and requires consultation with a doctor.

Conditional Use (Caution Required): Caution is mandated for patients with a history of Gastrointestinal (GI) ulcers or bleeding, uncontrolled hypertension, impaired hepatic function (liver disease), or impaired renal function (kidney disease). Elderly patients (65 and older) are at an increased risk for serious GI complications.

What should I know about interactions with other medicines?

Proxalin-Plus Interactions with other medicines and products

The official interaction profile for Proxalin-Plus is structured by documented patterns that define co-administration constraints, drawing exclusively from governmental regulatory information.


Contraindicated Combinations and Substances

Co-administration with any other acetaminophen-containing product is strictly prohibited to prevent the risk of severe hepatotoxicity. Combination with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including analgesic aspirin, is also contraindicated due to the additive risk of serious gastrointestinal bleeding and ulceration. Use is further prohibited in the peri-operative setting of Coronary Artery Bypass Graft (CABG) surgery.


Pharmacokinetic and Pharmacodynamic Risk

Proxalin-Plus reduces the renal clearance of certain medicines, leading to increased systemic exposure. This applies to substances such as Lithium and Methotrexate, which may accumulate to toxic levels. A significant pharmacodynamic risk is evident with Anticoagulants, Antiplatelet agents, and SSRIs, all of which significantly increase the documented risk of gastrointestinal bleeding. Additionally, the antihypertensive effect of ACE Inhibitors and ARBs may be officially diminished.


Timing and Population Constraints

To preserve the antiplatelet action of low-dose aspirin, a mandatory time separation of at least 2 hours is required between the two doses. Chronic, heavy alcohol consumption is documented to increase the risk of both GI bleeding and severe liver damage. The combination of Proxalin-Plus with ACE Inhibitors or ARBs carries a greater risk of renal impairment in elderly patients.

Mechanism of Action

How Proxalin-Plus Works: Mechanisms of Action

Peripheral Blockade of Inflammatory Mediators

The Naproxen component engages the mechanism of non-selective inhibition of the Cyclooxygenase-1 ( COX-1) and Cyclooxygenase-2 ( COX-2) enzymes throughout the body.

This action prevents the synthesis of prostaglandins from arachidonic acid, reducing the chemical sensitization of nerve endings and limiting the accumulation of pro-nociceptive mediators at the tissue level.


Central Modulation of Nociception and Thermoregulation

Acetaminophen exerts its primary effects within the Central Nervous System (CNS) by limiting prostaglandin synthesis in the hypothalamus to adjust the central thermoregulatory set point. Furthermore, the drug's metabolite modulates key central nociceptive signal pathways, potentially involving TRPV1 receptors and the endocannabinoid system, to inhibit the overall transmission and processing of nociceptive signals in the brain and spinal cord.


Dual-Site Mechanistic Synergy

The combination achieves a coordinated effect through mechanistic independence: Naproxen targets the peripheral cyclooxygenase activity, while Acetaminophen focuses on central nociceptive signal pathways and thermoregulatory mechanisms. This dual-site mechanism results in a complementary action to adjust the inflammatory cascade and nociceptive signaling simultaneously.

Dosage and Administration Information

Proxalin-Plus is an oral tablet that is administered strictly by the oral route. The instructions dictate a general dosing principle: the medicine must be administered using the lowest effective dosage for the shortest duration of time consistent with the therapeutic goal. The standard regimen for the NSAID component of the fixed-dose combination is typically scheduled for twice daily (BID) administration.

The tablet must be swallowed whole with a full glass of water to ensure proper delivery and transit. While the medicine may be taken with food or milk, this action may delay the rate of absorption. Certain formulations, such as those with specialized delayed-release or extended-release coatings, must not be crushed, broken, or chewed to preserve the integrity of the delivery system and ensure the correct release profile.

Administration Constraints

Constraint Entity Guideline
Duration of Use Generally short-term use, consistent with guidance for acute pain relief.
Dosing in Older Adults Therapy must be initiated with the lowest effective dose.
Renal Function Use is not recommended for patients with moderate to severe renal impairment (creatinine clearance <30 mL/min).

These administration guidelines structure the use of Proxalin-Plus by defining the precise parameters of its ingestion, the required frequency, and necessary dose constraints for specific populations, all of which are essential to the protocol.

Recent Clinical Evidence

Proxalin-Plus: Recent Clinical Evidence


Evidence for Use in Acute Post-Procedure Pain

The research describing the clinical evaluation of Proxalin-Plus is built upon short-term, randomized controlled trials (RCTs). These studies typically compare the medicine against both a placebo and its individual active components taken alone. This research was studied for adult patients experiencing pain after procedures such as surgical tooth extractions or minor orthopedic operations.

Studies monitored patient-reported outcomes related to physical discomfort and the time elapsed before a patient needed additional pain medication. Findings describe patterns observed in the studies where the combination was associated with differences in patient-reported outcomes describing perceived discomfort compared to a placebo. The primary findings describe patterns related only to the immediate post-procedure observation period; follow-up durations were limited, typically covering the initial 12 to 24 hours after a single dose.


Evidence for Symptoms of Primary Dysmenorrhea

The medicine was evaluated in research exploring how symptoms change over time in conditions characterized by fluctuating or episodic manifestations, specifically primary dysmenorrhea (menstrual cramps). The main studies used a specialized crossover design, where adult women with this condition were observed over different menstrual cycles for comparison.

Clinical trials monitored changes in patient-reported pain intensity scores during episodes of dysmenorrhea. Research describes how symptom evolution was observed in some studies to be associated with the combination compared to placebo. However, these trials are relevant in evidence describing how symptoms are measured during short-term or episodic symptom patterns.


Research Gaps and What Remains Uncertain

One key limitation is that the results apply only to the populations studied—primarily healthy adults undergoing standardized procedures. The reliance on single-dose and short-course data means that there is limited information for long-term outcomes or durability of response. Comparative evidence is lacking in some areas concerning how this specific combination performs against other treatments. Research provides context but not individual predictions. Findings describe group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Proxalin-Plus (FAQ)

Q: What is the main difference between Proxalin-Plus and a regular pain reliever?

Proxalin-Plus is officially defined as a fixed-dose combination product containing two distinct active ingredients, Acetaminophen and Naproxen Sodium. This dual composition allows it to address pain through two complementary mechanisms—one central and one peripheral—according to official documents. This differs from regular pain relievers, which typically rely on a single ingredient.

Q: Is Proxalin-Plus the same as [Common pain reliever name]?

No. Proxalin-Plus is a combination product featuring two separate medicines, an NSAID and an analgesic/antipyretic. Most common pain relievers are single-ingredient products. According to regulatory documents, fixed-dose combination products are distinct from their single-ingredient counterparts.

Q: How quickly can someone expect Proxalin-Plus to start working?

Official product information describes that the pain-relieving component, Naproxen, is typically associated with the onset of relief beginning within approximately 1 hour of administration. The actual timing of symptom improvement can vary among individuals. The administration instructions suggest that taking the medicine with food or milk may slightly delay this rate of absorption.

Q: How long does the effect of a single dose of Proxalin-Plus typically last?

The therapeutic effect is generally expected to align with the official dosing schedule for the NSAID component, which is often scheduled for administration twice daily. This suggests a duration of effect that can last between 8 to 12 hours.

Q: Is it safe to use Proxalin-Plus for long periods of time?

Regulatory guidance dictates that the medicine should be used at the lowest effective dosage for the shortest duration of time consistent with the treatment goal. Prolonged use is advised to be supervised by a healthcare professional, with monitoring considered due to potential serious risks.

Q: Are there any known interactions between Proxalin-Plus and common vitamins?

Official documentation describes the need for patients to inform their healthcare professional of all concomitant medications and supplements, including vitamins and herbs. While specific vitamin interactions are not typically detailed in general product labeling, disclosing all concurrent products helps to prevent potential interactions.

Q: What is the expected long-term safety profile of Proxalin-Plus?

Official labeling indicates that the risk of serious adverse events, including cardiovascular events (like heart attack or stroke) and gastrointestinal bleeding, is documented to increase with the duration of use. For patients on long-term treatment, periodic monitoring of certain blood parameters may be considered.

Q: Why do people sometimes say Proxalin-Plus is 'stronger' than single-ingredient alternatives?

The product's composition is designed to provide enhanced efficacy compared to using either component alone. This is because the two active ingredients target pain through two independent mechanisms of action—one central and one peripheral—which work together to address pain and inflammation.

Q: Can Proxalin-Plus cause drowsiness or affect my ability to drive?

The medicine is associated with central nervous system side effects, including dizziness and, less commonly, somnolence (drowsiness), as listed in adverse reaction reports. Regulatory information indicates that caution is necessary when engaging in activities such as driving or operating machinery due to potential CNS effects.

Q: Are there any specific foods or drinks that should be avoided while taking Proxalin-Plus?

Taking the medicine with food or milk is permitted, and doing so may help minimize the risk of stomach upset, although it can delay the rate of absorption. Regulatory warnings strictly document that chronic, heavy alcohol consumption increases the risk of serious adverse events.

Q: What happens if I miss a scheduled dose of Proxalin-Plus?

General regulatory guidance outlines the protocol for a missed dose: it may be taken when remembered, but regulatory documents advise that a double dose should be avoided, especially when nearly time for the next scheduled dose. This aligns with the principle of using the lowest effective dosage.

Q: Is there a maximum number of days or weeks Proxalin-Plus is approved for use?

The medicine is generally indicated for short-term use. For over-the-counter strengths, regulatory labeling often notes that use should not extend beyond a period of 10 days without medical consultation, as the medicine is generally indicated for short-term use.

Q: What should I do if I notice a rash after taking Proxalin-Plus?

Regulatory guidance describes this event as a possible serious allergic event. The product label states that the medicine must be discontinued and immediate medical attention should be sought if a rash or severe skin reaction occurs, as described in the allergy alert warnings.

Q: Can Proxalin-Plus make me feel dizzy or lightheaded?

Yes, regulatory documents list dizziness as one of the commonly reported side effects of this medication. Lightheadedness is a related symptom that can be associated with the central nervous system effects cited in product labeling.

Q: Are there different strengths or versions of Proxalin-Plus available?

Yes, the product is described in official labeling as a fixed-dose combination, and different strengths of the oral tablet may be available. The specific strength available is noted in the product's official labeling, and the appropriate strength for use is based on the prescribed regimen or the product's directions.

Q: Can Proxalin-Plus be taken on an empty stomach?

The medicine can be taken with or without food, as noted in the administration instructions. However, official information suggests that taking it with food or milk may help to minimize the risk of stomach upset.

Q: Does Proxalin-Plus interact with common cold or flu medicines?

Many common cold and flu relief medicines contain the ingredient acetaminophen. Regulatory documentation strictly prohibits co-administration with any other acetaminophen-containing product due to the severe risk of liver damage.

Q: Is it true that Proxalin-Plus is sometimes used for headache relief?

Yes, the components of Proxalin-Plus are officially indicated for minor aches and pains, which includes headache relief. Official documents list headache as an approved use for products containing these components.

Q: Can Proxalin-Plus affect sleep or cause insomnia?

Adverse reactions related to the nervous system, such as insomnia (sleeplessness), have been reported in product labeling. The official documentation indicates that persistent sleeplessness may warrant evaluation by a healthcare professional.

Q: Does the medicine come in a tablet or capsule form?

The product is officially supplied as an oral tablet (fixed-dose combination), as described in its regulatory labeling.

Q: Is Proxalin-Plus available without a prescription in some countries?

The regulatory classification of this medicine as Prescription (Rx) or Over-the-Counter (OTC) can vary depending on the country and the specific dose or strength of the combination product. This determination is made by national health authorities.

Q: Can Proxalin-Plus cause changes in appetite?

While not listed as a common side effect, regulatory documents describe that symptoms like loss of appetite (anorexia) may be signs of a severe adverse reaction, such as liver damage, and warrant immediate medical evaluation.

Q: Is it safe to take Proxalin-Plus with other medications for allergies?

Official documentation describes the requirement for disclosing all medicines to a healthcare professional to assess potential interactions. This is because certain components in allergy medications may interact with one of the ingredients in Proxalin-Plus, potentially increasing the risk of adverse effects.

Q: Is it normal to feel a slight stomach upset after taking Proxalin-Plus?

Yes, official regulatory documentation lists common side effects which include gastrointestinal upset symptoms. These commonly reported symptoms include dyspepsia (heartburn) and nausea.

Q: Can Proxalin-Plus affect laboratory test results?

Official labeling advises that the drug may interfere with some laboratory diagnostic tests. The label further advises that certain blood tests should be considered for monitoring during long-term NSAID treatment.

How should Proxalin-Plus be stored and disposed of?

Official Storage and Disposal Requirements

The medicine's regulatory labeling strictly defines the conditions necessary to maintain product integrity and safety.

Storage Condition Type Mandatory Requirements
Temperature Controlled Room Temperature: 20 C to 25 C (68 F to 77 F). Do not freeze.
Protection Must be protected from light and stored in a dry place (away from moisture).
Packaging Store in the original container and keep the container tightly closed.
Child Safety Keep out of the sight and reach of children.

Disposal instructions require the product to be handled as pharmaceutical waste. Unused or expired Proxalin-Plus must be discarded according to local regulatory requirements or an official take-back program. It should not be flushed down a toilet or placed in household trash unless otherwise instructed by a national authority.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Proxalin-Plus found in:

A-Z Index: